Hikma Pharmaceutic (NASDAQ:HKMPF) was upgraded by Zacks Investment Research from a “hold” rating to a “strong-buy” rating in a research report issued to clients and investors on Wednesday. The brokerage currently has a $27.00 target price on the stock.
According to Zacks, “Hikma Pharmaceuticals PLC develops, manufactures and markets pharmaceutical products. Its brand portfolio includes branded, injectables and generic. Branded segment offers dosage forms and strengths in the anti-infective, cardiovascular, diabetes, central nervous system, oncology and respiratory. Injectables segment offers dosage for CNS, controlled substances, anti-infective, cardiovascular and oncology in form of liquid, semi-liquid and powdered form. Generics segment offers dosage for therapeutic including analgesic, anti-infective, anti-inflammatory, cardiovascular, CNS, respiratory and hormonal. Hikma Pharmaceuticals PLC is based in London, the United Kingdom. “
Separately, Morgan Stanley upgraded shares of Hikma Pharmaceutic from an “equal weight” rating to an “overweight” rating in a report on Wednesday, November 16th.
Hikma Pharmaceutic (NASDAQ:HKMPF) remained flat at $23.40 during trading on Wednesday. Hikma Pharmaceutic has a 1-year low of $20.43 and a 1-year high of $35.25. The stock’s 50 day moving average price is $22.01 and its 200 day moving average price is $26.58. The company has a market capitalization of $5.29 billion and a price-to-earnings ratio of 28.61.
Get a free copy of the Zacks research report on Hikma Pharmaceutic (HKMPF)
For more information about research offerings from Zacks Investment Research, visit Zacks.com